Woodline Partners’s Aclaris Therapeutics ACRS Stock Holding History

Woodline Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.52M	Buy	1,611,054 +125,431	+8%	+$559K	0.03%	569
2026 Q1	$5.57M	Buy	1,485,623 +743,614	+100%	+$2.51M	0.02%	641
2025 Q4	$2.23M	Buy	+742,009	New	+$1.87M	0.01%	758
2023 Q4	–	Sell	-170,230	Closed	-$1.17M	–	469
2023 Q3	$1.17M	Buy	170,230 +68,731	+68%	+$587K	0.01%	435
2023 Q2	$1.05M	Sell	101,499 -124,703	-55%	-$1.13M	0.01%	482
2023 Q1	$1.83M	Sell	226,202 -376,317	-62%	-$4.78M	0.02%	431
2022 Q4	$9.49M	Sell	602,519 -94,488	-14%	-$1.52M	0.13%	220
2022 Q3	$11M	Buy	697,007 +75,450	+12%	+$1.19M	0.15%	189
2022 Q2	$8.68M	Buy	+621,557	New	+$8.71M	0.13%	193
2021 Q4	–	Sell	-594,768	Closed	-$10.7M	–	701
2021 Q3	$10.7M	Buy	+594,768	New	+$9.53M	0.17%	153

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Woodline Partners's ACRS Position: Q2 2026 in Review

Woodline Partners increased its Aclaris Therapeutics (ACRS) stake by 8.4% in Q2 2026, buying an estimated $559K and bringing the position to 1,611,054 shares worth $8.52M. The position accounts for 0.03% of the portfolio, ranked #569.

Woodline Partners first reported a position in ACRS in Q3 2021 and has held it in 10 quarters since. The position peaked at $11M in Q3 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Woodline Partners held 1,611,054 shares of Aclaris Therapeutics worth $8.52M as of Q2 2026.
Woodline Partners bought 125,431 Aclaris Therapeutics shares in Q2 2026, an estimated $559K.
Aclaris Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #569 holding.
Woodline Partners first reported a position in Aclaris Therapeutics in Q3 2021 and has held it in 10 quarters since.
Woodline Partners's Aclaris Therapeutics position peaked at $11M in Q3 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.